These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35967385)

  • 41. Regulation of Hypoxic-Adenosinergic Signaling by Estrogen: Implications for Microvascular Injury.
    Cassavaugh J; Qureshi N; Csizmadia E; Longhi MS; Matyal R; Robson SC
    Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging Roles of Purinergic Signaling in Diabetes.
    Fotino C; Dal Ben D; Adinolfi E
    Med Chem; 2018; 14(5):428-438. PubMed ID: 29485002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
    Pant AB; Wang Y; Mielcarz DW; Kasper EJ; Telesford KM; Mishra M; Haque A; Channon JY; Kasper LH; Begum-Haque S
    J Neuroimmunol; 2017 Feb; 303():22-30. PubMed ID: 28087077
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interactions among adenosine deaminase, adenosine A(1) receptors and dopamine D(1) receptors in stably cotransfected fibroblast cells and neurons.
    Torvinen M; Ginés S; Hillion J; Latini S; Canals M; Ciruela F; Bordoni F; Staines W; Pedata F; Agnati LF; Lluis C; Franco R; Ferré S; Fuxe K
    Neuroscience; 2002; 113(3):709-19. PubMed ID: 12150791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis.
    Bernardo-Faura M; Rinas M; Wirbel J; Pertsovskaya I; Pliaka V; Messinis DE; Vila G; Sakellaropoulos T; Faigle W; Stridh P; Behrens JR; Olsson T; Martin R; Paul F; Alexopoulos LG; Villoslada P; Saez-Rodriguez J
    Genome Med; 2021 Jul; 13(1):117. PubMed ID: 34271980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases.
    Ibañez-Vega J; Vilchez C; Jimenez K; Guevara C; Burgos PI; Naves R
    J Autoimmun; 2021 Sep; 123():102702. PubMed ID: 34311143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases.
    Morandi F; Horenstein AL; Rizzo R; Malavasi F
    Mediators Inflamm; 2018; 2018():7019398. PubMed ID: 29769837
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytokines as Mediators of Neuroinflammation in Experimental Autoimmune Encephalomyelitis.
    Gogoleva VS; Atretkhany KN; Drutskaya MS; Mufazalov IA; Kruglov AA; Nedospasov SA
    Biochemistry (Mosc); 2018 Sep; 83(9):1089-1103. PubMed ID: 30472948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NADH oxidase-dependent CD39 expression by CD8(+) T cells modulates interferon gamma responses via generation of adenosine.
    Bai A; Moss A; Rothweiler S; Serena Longhi M; Wu Y; Junger WG; Robson SC
    Nat Commun; 2015 Nov; 6():8819. PubMed ID: 26549640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adenosine signaling and the immune system: When a lot could be too much.
    Antonioli L; Fornai M; Blandizzi C; Pacher P; Haskó G
    Immunol Lett; 2019 Jan; 205():9-15. PubMed ID: 29702147
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting adenosinergic pathway and adenosine A
    Abouelkhair MA
    Med Hypotheses; 2020 Nov; 144():110012. PubMed ID: 32590324
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Adenosinergic System in Diabetic Retinopathy.
    Vindeirinho J; Santiago AR; Cavadas C; Ambrósio AF; Santos PF
    J Diabetes Res; 2016; 2016():4270301. PubMed ID: 27034960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development.
    Ben-Nun A; Kaushansky N; Kawakami N; Krishnamoorthy G; Berer K; Liblau R; Hohlfeld R; Wekerle H
    J Autoimmun; 2014 Nov; 54():33-50. PubMed ID: 25175979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.
    Horenstein AL; Bracci C; Morandi F; Malavasi F
    Front Immunol; 2019; 10():760. PubMed ID: 31068926
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of myeloid cells by adenosine signaling.
    Cekic C
    Curr Opin Pharmacol; 2020 Aug; 53():134-145. PubMed ID: 33022543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adenosine deaminase-adenosine pathway in hemolysis-associated pulmonary hypertension.
    Tofovic SP; Jackson EK; Rafikova O
    Med Hypotheses; 2009 Jun; 72(6):713-9. PubMed ID: 19237250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glutamate, T cells and multiple sclerosis.
    Levite M
    J Neural Transm (Vienna); 2017 Jul; 124(7):775-798. PubMed ID: 28236206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adenosinergic cardioprotection: multiple receptors, multiple pathways.
    Peart JN; Headrick JP
    Pharmacol Ther; 2007 May; 114(2):208-21. PubMed ID: 17408751
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway.
    Sadek MA; Kandil EA; El Sayed NS; Sayed HM; Rabie MA
    Int Immunopharmacol; 2023 Feb; 115():109647. PubMed ID: 36584570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Control of Gut Inflammation by Modulation of Purinergic Signaling.
    Vuerich M; Mukherjee S; Robson SC; Longhi MS
    Front Immunol; 2020; 11():1882. PubMed ID: 33072065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.